Insight Molecular Diagnostics Inc. (IMDX)
NASDAQ: IMDX · Real-Time Price · USD
1.970
+0.310 (18.67%)
At close: Nov 20, 2026, 4:00 PM EST
1.940
-0.030 (-1.52%)
After-hours: Nov 20, 2026, 7:57 PM EST
IMDX Revenue
Insight Molecular Diagnostics had revenue of $239.00K in the quarter ending June 30, 2026, a decrease of -53.86%. This brings the company's total for the last twelve months to $1.67M, down -60.77% year-over-year. In the year 2025, Insight Molecular Diagnostics had annual revenue of $4.06M with 115.58% growth. That makes Insight Molecular Diagnostics the 42,443rd largest company in the world by revenue and 5,800th in the United States.
Revenue (ttm)
$1.67M
Revenue Growth
-60.77%
P/S Ratio
32.74
Revenue / Employee
$33,948
Employees
58
Market Cap
64.47M
Revenue by Geography
- United States 4.03M 99.4%
- Europe 24.00K 0.6%
Fiscal year ended Dec 31, 2025 See the full IMDX breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.06M | 2.17M | 115.58% |
| Dec 31, 2024 | 1.88M | 378.00K | 25.15% |
| Dec 31, 2023 | 1.50M | 545.00K | 56.89% |
| Dec 31, 2022 | 958.00K | -1.24M | -56.41% |
| Dec 31, 2021 | 2.20M | 982.00K | 80.76% |
| Dec 31, 2020 | 1.22M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Myriad Genetics | 803.60M |
| Fulgent Genetics | 330.28M |
| MDxHealth | 114.01M |
| Biodesix | 105.21M |
| Burning Rock Biotech | 73.70M |
| Exagen | 72.30M |
| XWELL | 28.28M |
| Precipio | 27.76M |
IMDX News
- 1 day ago - Insight Molecular price target lowered to $9 from $12 at Lake Street - TheFly
- 1 day ago - Insight Molecular enrolls first patients in GALACTIC registry study - TheFly
- 1 day ago - iMDx Expands GraftAssure Utilization as First Patient Samples Arrive for GALACTIC Registry Study - GlobeNewsWire
- 4 days ago - Insight Molecular Diagnostics 8.3M share Spot Secondary priced at $1.75 - TheFly
- 4 days ago - Insight Molecular Diagnostics Announces Pricing of $15 Million Public Offering - GlobeNewsWire
- 4 days ago - Insight Molecular price target lowered to $4 from $8 at Lucid Capital - TheFly
- 5 days ago - Insight Molecular Diagnostics reports Q3 EPS (10c), two estimates (22c) - TheFly
- 5 days ago - Insight Molecular Diagnostics Earnings Call Transcript: Q3 2026 - Transcripts